Targeting KRAS with INspire platform
KRAS is an oncogenic protein which is a key driver of cancer progression and is frequently mutated in various human malignancies.
Its aberrant activation leads to uncontrolled cell proliferation, evasion of apoptosis, and enhanced tumor cell survival. Targeting KRAS has been a major focus in cancer therapeutics, and recent advances in developing small molecule inhibitors hold promise for effective treatment strategies against KRAS-driven cancers. However, these therapies have been demonstrated to suffer from rapid development of resistance by tumors and drug toxicities. INspire offers a new Mechanism of Action (MoA) and by blocking protein-protein interactions and downstream KRAS signaling. INspire based therapies are expected to be less toxic due to the high specificity of biologics and should have reduced resistance by the tumors.